Research news

Researchers perform thousands of mutations to understand amyotrophic lateral sclerosis

Researchers from IBEC and CRG in Barcelona use a technique called high-throughput mutagenesis to study Amyotrophic Lateral Sclerosis (ALS), with unexpected results.

Results showed that aggregation of TDP-43 is not harmful but actually protects cells, changing our understanding of ALS and opening the door to radically new therapeutic approaches.

Amyotrophic lateral sclerosis (ALS) is a devastating and incurable nervous system disease that affects nerve cells in the brain and spinal cord, causing loss of muscle control and normally death within a few years of diagnosis. In ALS, like in other neurodegenerative diseases, specific protein aggregates have long been recognized as the pathological hallmarks, but it is not clear whether they represent the actual cause of the disease. Indeed, alleviating aggregation has repeatedly failed as a therapeutic strategy when trying to treat neurodegenerative diseases such as Alzheimer’s disease.

Read more…

Other news

IBEC launches a challenge at the 2nd Innovation Days

Last 9th November 75 participants from different fields participated in the 2nd edition of the Innovation Days (i-Days) organised by EIT Health. Thirty-two locations around Europe hosted the i-Days and for the second time in a row, IBEC was involved in many parts of the workshop held in Barcelona.

I-Days promote health innovation among university students through one-to-two-day programmes held at academic institutions around Europe. Students receive an introduction to practical health innovation tools and work in multidisciplinary teams to tackle real life health challenges posed by EIT Health projects, local organisations and private corporations. The event counted with inspirational speakers and coaches that introduced students to practical tools in innovation, design thinking and pitching ideas.

Read more…